Capsomer vaccines protect mice from vaginal challenge with human papillomavirus

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Wu, Wai Hong ^a   Gersch, Elizabeth ^b   Kwak, Kihyuck ^a   Jagu, Subhashini ^a   Karanam, Balasubramanyam ^a   Huh, Warner K ^c   Garcea, Robert L ^b   Roden, Richard B S ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c University of Alabama   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSOMER VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROTECTION; PROVOCATION TEST; VAGINA; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNOLOGY; PAPILLOMA VIRUS; PATHOGENICITY; VIRION; VIROLOGY; VIRUS CAPSID;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; CAPSID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VAGINA; VIRION;

EID: 80055117975     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027141     Document Type: Article

References (50)

1. zur Hausen H, (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev Cancer 2: 342-350.
2. Roden R, Wu TC, (2006) How will HPV vaccines affect cervical cancer? Nat Rev Cancer 6: 753-763.
3. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6: 271-278.
4. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, et al. (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459-1466.
5. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, et al. (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369: 2161-2170.
6. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
7. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, et al. (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369: 1693-1702.
8. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, et al. (2011) Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 364: 401-411.
9. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 199: 926-935.
10. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, et al. (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111: 278-285.
11. Karanam B, Jagu S, Huh WK, Roden RB, (2009) Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol 87: 287-299.
12. Parkin DM, (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030-3044.
13. Li M, Beard P, Estes PA, Lyon MK, Garcea RL, (1998) Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly. J Virol 72: 2160-2167.
14. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC, (2000) Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5: 557-567.
15. Li M, Cripe TP, Estes PA, Lyon MK, Rose RC, et al. (1997) Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol 71: 2988-2995.
16. Chen XS, Casini G, Harrison SC, Garcea RL, (2001) Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J Mol Biol 307: 173-182.
17. Schadlich L, Senger T, Kirschning CJ, Muller M, Gissmann L, (2009) Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity. Vaccine 27: 1511-1522.
18. Schadlich L, Senger T, Gerlach B, Mucke N, Klein C, et al. (2009) Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol 83: 7690-7705.
19. Yuan H, Estes PA, Chen Y, Newsome J, Olcese VA, et al. (2001) Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol 75: 7848-7853.
20. Rose RC, White WI, Li M, Suzich JA, Lane C, et al. (1998) Human papillomavirus type 11 recombinant L1 capsomeres induce virus- neutralizing antibodies. J Virol 72: 6151-6154.
21. Jagu S, Kwak K, Garcea RL, Roden RB, (2010) Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine 28: 4478-4486.
22. Combita AL, Touze A, Bousarghin L, Christensen ND, Coursaget P, (2002) Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76: 6480-6486.
23. Fligge C, Giroglou T, Streeck RE, Sapp M, (2001) Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. Virology 283: 353-357.
24. Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, et al. (2007) A protective and broadly cross-neutralizing epitope of Human Papillomavirus L2. J Virol 81: 13927-13931.
25. Laniosz V, Nguyen KC, Meneses PI, (2007) Bovine papillomavirus type 1 infection is mediated by SNARE syntaxin 18. J Virol 81: 7435-7448.
26. Rubio I, Seitz H, Canali E, Sehr P, Bolchi A, et al. (2011) The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies. Virology 409: 348-359.
27. Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, et al. (2005) Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 337: 365-372.
28. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T, (1999) Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 73: 6188-6190.
29. Roden RB, Weissinger EM, Henderson DW, Booy F, Kirnbauer R, et al. (1994) Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol 68: 7570-7574.
30. Roden RB, Yutzy WHt, Fallon R, Inglis S, Lowy DR, et al. (2000) Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270: 254-257.
31. Chackerian B, Lenz P, Lowy DR, Schiller JT, (2002) Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169: 6120-6126.
32. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, et al. (1995) Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 92: 11553-11557.
33. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
34. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, et al. (2011) HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29: 2011-2014.
35. Gambhira R, Jagu S, Karanam B, Gravitt PE, Culp TD, et al. (2007) Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N-terminus of HPV16 minor capsid antigen L2. J Virol 81: 13927-13931.
36. Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, et al. (2009) Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 101: 782-792.
37. Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, et al. (2010) In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 8: 260-270.
38. Garcon N, Van Mechelen M, (2011) Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems. Expert Rev Vaccines 10: 471-486.
39. Varsani A, Williamson AL, de Villiers D, Becker I, Christensen ND, et al. (2003) Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol 77: 8386-8393.
40. Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T, (2008) Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol 80: 841-846.
41. Schellenbacher C, Roden R, Kirnbauer R, (2009) Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 83: 10085-10095.
42. Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, et al. (2007) Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem 282: 31803-31811.
43. Trus BL, Roden RB, Greenstone HL, Vrhel M, Schiller JT, et al. (1997) Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution. Nat Struct Biol 4: 413-420.
44. Modis Y, Trus BL, Harrison SC, (2002) Atomic model of the papillomavirus capsid. Embo J 21: 4754-4762.
45. McCarthy MP, White WI, Palmer-Hill F, Koenig S, Suzich JA, (1998) Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J Virol 72: 32-41.
46. Capron A, Riveau G, Grzych JM, Boulanger D, Capron M, et al. (1994) Development of a vaccine strategy against human and bovine schistosomiasis. Background and update. Trop Geogr Med 46: 242-246.
47. Capron A, Riveau G, Capron M, Trottein F, (2005) Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol 21: 143-149.
48. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, et al. (1996) Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223: 174-184.
49. Buck CB, Pastrana DV, Lowy DR, Schiller JT, (2005) Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 119: 445-462.
50. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13: 857-861.